AzTrials
AzTrials

Morbid ObesityNCT01564732

Multicenter Prospective Randomized Controlled Trial of Plicated Laparoscopic Adjustable Gastric Banding

A study testing Standard-LAGB and Plicated-LAGB in people with Morbid Obesity, run by Dana Portenier, MD at 1 site in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The purpose of this study is to compare plicated laparoscopic adjustable gastric banding (PLAGB) to standard laparoscopic adjustable gastric banding (SLAGB) in a prospective randomized clinical trial. Read more about this study

Who is it for?
Ages 18 to 60 years
Conditions the study is for
Morbid Obesity
What is being tested?
Standard-LAGB and Plicated-LAGB
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
17 participants
Where
1 siteUnited States
Study dates
Sep 2013to Apr 2015
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 60 years
  • All sexes
  • No healthy volunteers
  • Adult

Inclusion Criteria: Subjects must meet the following criteria to be eligible for study entry:

  1. Age between 18-60 years,
  2. Morbidly obese:
  3. BMI > 40, or b. BMI > 35 + co-morbid obesity related disease condition c)BMI < or equal to 55

Exclusion Criteria: Subjects meeting the following criteria will be excluded from study entry:

  1. Patients with any major medical problems contraindicating surgery (eg.myocardial infarct within last 6 months, cancer within last 5 years, end stage renal/liver disease, etc.)
  2. Patients with a medically treatable cause of obesity (eg. untreated hypothyroidism, Prader-Willi, etc.)
  3. Patients who elect to undergo a surgery other than a PLAGB or SLAGB
  4. Patient who is unwilling to be randomized to PLAGB or SLAGB
  5. Pregnant or planning pregnancy within 12 months
  6. Alcohol or drug addiction
  7. Established infection anywhere in the body at the time of surgery
  8. Previous history of bariatric surgery, gastric surgery, intestinal obstruction, or adhesive peritonitis.
  9. Family or patient history of autoimmune disease
  10. Hiatal Hernia > 3cm (as reported per radiology on pre-operative swallow study)

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania, 15213

Other trials in United States

About this study

Official title: Multicenter Prospective Randomized Clinical Trial of Plicated Laparoscopic Adjustable Gastric Banding

The purpose of this study is to compare plicated laparoscopic adjustable gastric banding (PLAGB) to standard laparoscopic adjustable gastric banding (SLAGB) in a prospective randomized clinical trial. We hypothesize the plicated procedure will provide greater short- and long-term excess weight loss than the standard procedure. There exists little prospective randomized data regarding this topic and the recent position statement from the American Society for Metabolic and Bariatric Surgery (ASMBS) encourages this type of study. Further information on background and design of this study are provided in the detailed description.

Read the detailed description

Morbid obesity is a major problem affecting the lives of millions in the US. As of 2008, overall prevalence of obesity as defined by body mass index (BMI) greater than 30 kg/m2 was 33.8%.1 Obesity adversely affects the lives of millions of Americans by increasing the risk for co-morbid conditions such as diabetes mellitus, obstructive sleep apnea, hypertension, and even certain cancers.2-4 The laparoscopic adjustable gastric banding (LAGB) procedure is a safe, effective, and durable treatment option for refractory morbid obesity and its related health consequences.5 This minimally invasive technique is now a popular approach for bariatric surgery, and it offers obvious advantages such as decreased operating time, shorter hospital stay (often same day surgery), and favorable complication rates as compared with other bariatric procedures.4,5

One of the biggest drawbacks to LAGB [when compared to the 'gold standard' of bariatric surgery: Roux-en-Y gastric bypass] is that patients tend to have a slower, less dramatic weight loss in the first few months after surgery.5-7 In addition, the LAGB procedure is associated with an approximate 3% chance of "band slippage" complications.8 In order to address some of these issues modifications in the technique of LAGB surgery have been made. Techniques such as a "pars-flaccida approach" to tissue dissection and the placement of plication sutures to "anchor" the redundant stomach around the newly placed band device were introduced and shown to have positive results in reducing band complication rates.8 More recently, sleeve gastrostomy procedures (the greater curvature and significant portion of the body of the stomach is resected over a sizing bougie; leaving a narrow 'sleeve' of stomach) have also become popular in treating patients with morbid obesity.9 Combining these concepts, a modified technique of plicated LAGB was introduced.

At the time of LAGB placement, plication sutures can be placed along the body \& greater curvature of the stomach to "tighten" and "cinch up" the stomach in a sleeve-like orientation. It was recently reported that this modified technique of plicated LAGB could result in lower band slippage complication rates and faster, early weight loss.8

However, as of today there exists no prospective, randomized study that compares the outcomes of this modified surgical technique to the standard procedure (SLAGB).

This is a prospective randomized clinical trial comparing PLAGB versus SLAGB. All adult (age older than 18 years) morbidly obese patients meeting NIH criteria for bariatric surgery (BMI > 35 + co-morbid disease or BMI > 40) who are undergoing bariatric surgery at the Duke Metabolic and Weight Loss Surgery Center and the University of Pittsburgh Medical Center will be recruited. All enrolled patients will be randomly assigned to either the SLAGB (control) group or the PLAGB (study) group. Variables to be studied include patient age, gender, ethnicity, co-morbid disease conditions, height, weight, BMI, intra-operative data such as operative time and blood loss, and post-operative outcomes including length of hospital stay, complication rates, weight loss, and co-morbid disease resolution. In addition, each patient will complete standardized surveys rating their satisfaction from surgery, their quality of life (OWL-QOL-17), and their sleepiness (Epworth Sleepiness Scale) at three distinct time intervals: pre-operatively and at weeks 24 \& 48.

Each subject will be followed and data collected according to the following schedule of visits:

Study Visit Schedule:

Year 1:

Visit 1: Screening Visit Visit 2: Day 0 (surgery) Visit 3: Week 2 (+/- 2 days) Visit 4: Week 4 (1 month) Visit 5: Week 8 (2 months) Visit 6: Week 12 (3 months) Visit 7: Week 16 (4 months) Visit 8: Week 20 (5 months) Visit 9: Week 24 (6 months) Visit 10: Week 30 Visit 11: Week 36 Visit 12: Week 42 Visit 13: Week 48

Year 2:

Visit 14: Week 60 Visit 15: Week 72 Visit 16: Week 84 Visit 17: Week 96

Year 3:

Visit 18: Week 128 (2.5 yrs) Visit 19: Week 156 (3 yrs)

Data gathered from PLAGB subjects will be compared to SLAGB controls. Pre- and post-operative care will be delivered consistent with our established protocols and standard practices; without regard to surgical approach. This includes a standard preoperative evaluation and patient education period followed by surgery. After surgery, patients are usually discharged from the hospital within the first 24 hours. Follow-up of patients will include an initial post-discharge clinic visit within the first 2 weeks, and subsequent visits scheduled at the time intervals as listed above. Subjects will be followed for a period of approximately 12 months.

This study compares a modified bariatric surgical approach. PLAGB will be studied and compared to the SLAGB procedure through a prospective randomized clinical trial.

Please note: Per our FDA approved modification of 6/18/2014, all study specific testing was eliminated, and only safety assessments were completed in the surgical office at 6 months and 1 year after surgery.

Conditions
Morbid Obesity
Being tested
Standard-LAGB, Plicated-LAGB
Keywords
morbid obesity, gastric band
Medical subject headings
Obesity, Morbid

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Standard-LAGBDevice

    Also called Standard Laparoscopic Adjustable Gastric Banding Surgery

    The laparoscopic adjustable gastric banding (LAGB) procedure is a safe, effective, and durable treatment option for refractory morbid obesity and its related health consequences.5 This minimally invasive technique is now a popular approach for bariatric surgery, and it offers obvious advantages such as decreased operating time, shorter hospital stay (often same day surgery), and favorable complication rates as compared with other bariatric procedures.

  • Plicated-LAGBDevice

    Also called Plicated Laparoscopic Adjustable Gastric Banding Surgery

    At the time of LAGB placement, plication sutures can be placed along the body \& greater curvature of the stomach to "tighten" and "cinch up" the stomach in a sleeve-like orientation. It was recently reported that this modified technique of plicated LAGB could result in lower band slippage complication rates and faster, early weight loss.

Study groups in NCT01564732
Study groupRoleWhat they receive
Standard-LAGBActive comparatorSubjects will be blinded and randomly assigned to the Standard Laparoscopic Gastric Banding(SLAGB)arm of the study. These subjects will receive the standard of care or standard laparoscopic gastric banding surgery.Subjects will be followed for a period of approximately 36 months.
Receives: Device: Standard-LAGB
Plicated-LAGBExperimentalSubjects will be blinded and randomly assigned to the Plicated Laparoscopic Gastric Banding(PLAGB)arm of the study. These subjects will receive the plicated laparoscopic gastric banding surgery with involves the placement of plication sutures to "anchor" the redundant stomach around the newly placed device. Subjects will be followed for a period of approximately 36 months.
Receives: Device: Plicated-LAGB

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Weight Loss

    Measured: 36 months

Secondary outcomes (5)
  1. Quality of Life

    Measured: 36 months

  2. Quantitative Change in Hypertension

    Systolic and Diastolic Blood Pressure will be measured over the scheduled visits and the change in preoperative and postoperative blood pressure will be determined. We will also assess the need for medications to treat hypertension before and after surgery.

    Measured: 36 months

  3. Quantitative Change in Diabetes

    Blood Sugar will be measured over the scheduled visits and the change in preoperative and postoperative glucose levels will be determined. We will also assess the need for medications to treat diabetes before and after surgery.

    Measured: 36 months

  4. Quantitative Change in Hyperlipidemia

    Lipid levels will be measured annually for 3 years and the change in preoperative and postoperative levels will be determined. We will also assess the need for medications to treat hyperlipidemia before and after surgery.

    Measured: 36 months

  5. Quantitative Change in Hypertriglyceridemia

    Triglyceride levels will be measured annually for 3 years and the change in preoperative and postoperative levels will be determined. We will also assess the need for medications to treat hypertriglyceridemia before and after surgery.

    Measured: 36 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Mar 2012 (estimated)
  2. Study startSep 2013
  3. Primary completionApr 2015
  4. Study completionApr 2015

Why it stopped: Sponsor withdrew funding.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
17 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01564732
Sponsor's protocol ID
Pro00033638
Status last verified
Jun 2016
First submitted
7 Mar 2012
Last updated
1 Jul 2016
Data monitoring committee
Yes

Publications

  • Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA. 2010 Jan 20;303(3):235-41. doi: 10.1001/jama.2009.2014. Epub 2010 Jan 13.

    PubMed 20071471
  • Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, Schoelles K. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004 Oct 13;292(14):1724-37. doi: 10.1001/jama.292.14.1724.

    PubMed 15479938
  • Sjostrom L, Narbro K, Sjostrom CD, Karason K, Larsson B, Wedel H, Lystig T, Sullivan M, Bouchard C, Carlsson B, Bengtsson C, Dahlgren S, Gummesson A, Jacobson P, Karlsson J, Lindroos AK, Lonroth H, Naslund I, Olbers T, Stenlof K, Torgerson J, Agren G, Carlsson LM; Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007 Aug 23;357(8):741-52. doi: 10.1056/NEJMoa066254.

    PubMed 17715408
  • Pories WJ. Bariatric surgery: risks and rewards. J Clin Endocrinol Metab. 2008 Nov;93(11 Suppl 1):S89-96. doi: 10.1210/jc.2008-1641.

    PubMed 18987275
  • Longitudinal Assessment of Bariatric Surgery (LABS) Consortium; Flum DR, Belle SH, King WC, Wahed AS, Berk P, Chapman W, Pories W, Courcoulas A, McCloskey C, Mitchell J, Patterson E, Pomp A, Staten MA, Yanovski SZ, Thirlby R, Wolfe B. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med. 2009 Jul 30;361(5):445-54. doi: 10.1056/NEJMoa0901836.

    PubMed 19641201
  • Gravante G, Araco A, Araco F, Delogu D, De Lorenzo A, Cervelli V. Laparoscopic adjustable gastric bandings: a prospective randomized study of 400 operations performed with 2 different devices. Arch Surg. 2007 Oct;142(10):958-61. doi: 10.1001/archsurg.142.10.958.

    PubMed 17938309
  • Cottam DR, Atkinson J, Anderson A, Grace B, Fisher B. A case-controlled matched-pair cohort study of laparoscopic Roux-en-Y gastric bypass and Lap-Band patients in a single US center with three-year follow-up. Obes Surg. 2006 May;16(5):534-40. doi: 10.1381/096089206776944913.

    PubMed 16687018
  • Hussain A, Mahmood H, El-Hasani S. Gastric plication can reduce slippage rate after laparoscopic gastric banding. JSLS. 2010 Apr-Jun;14(2):221-7. doi: 10.4293/108680810X12785289144241.

    PubMed 20932373
  • Lee CM, Cirangle PT, Jossart GH. Vertical gastrectomy for morbid obesity in 216 patients: report of two-year results. Surg Endosc. 2007 Oct;21(10):1810-6. doi: 10.1007/s00464-007-9276-y. Epub 2007 Mar 14.

    PubMed 17356932
  • Lancaster RT, Hutter MM. Bands and bypasses: 30-day morbidity and mortality of bariatric surgical procedures as assessed by prospective, multi-center, risk-adjusted ACS-NSQIP data. Surg Endosc. 2008 Dec;22(12):2554-63. doi: 10.1007/s00464-008-0074-y. Epub 2008 Sep 20.

    PubMed 18806945

Questions about this trial

What is this clinical trial studying?

A study testing Standard-LAGB and Plicated-LAGB in people with Morbid Obesity, run by Dana Portenier, MD at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 1 Jul 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 1 Jun 2016). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Weight Loss (time frame: 36 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01564732, which also lists 10 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jul 2016; AzTrials last refreshed its copy on 30 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in